3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Paclitaxel
143
pembrolizumab
121
Carboplatin
109
Bevacizumab
93
Cisplatin
69
Specimen Handling
62
olaparib
51
Magnetic Resonance Spectroscopy
51
Gemcitabine
41
Nivolumab
36
Biopsy
36
liposomal doxorubicin
34
Taxes
33
Cyclophosphamide
31
Blood Specimen Collection
31
niraparib
28
lenvatinib
26
Letrozole
26
Doxorubicin
26
Topotecan
25
Drug Therapy
25
Immunoglobulin G
23
Brachytherapy
22
fludarabine
21
atezolizumab
21
Radiotherapy
21
Disulfides
21
durvalumab
20
dostarlimab
19
Surveys and Questionnaires
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
STX-478
×
Gynecologic
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled